论文部分内容阅读
为探讨自体骨髓移植（ＡＢＭＴ）治疗恶性淋巴瘤的适应证及高效、低毒的预处理方案，对１１例有预后不良因素的恶性淋巴瘤进行ＡＢＭＴ治疗。１１例中初治１０例，复发１例，移植时中位年龄２７（１９～３７）岁。预处理方案主要为全身照射（８Ｇｙ）和以马法兰（Ｍｅｌ）为主的大剂量化疗（Ｍｅｌ１４０ｍｇ／ｍ￣２±Ｖｐ１６２００ｍｇ或＋Ａｒａ－Ｃ１ｇ／ｍ￣２±ＣＴＸ６０ｍｇ／ｋｇ）。造血重建后肿瘤局部补加照射２５～３０Ｇｙ。移植结果全部患者造血功能获得重建，无移植相关死亡。中位随访３５（１３～５０）个月，持续完全缓解率８１．８％，复发率１８．２％。本预处理方案的ＡＢＭＴ对高度恶性非霍奇金淋巴瘤和常规治疗反应不良的霍奇金病有良好疗效。
In order to investigate the indications of autologous bone marrow transplantation (ABMT) for treatment of malignant lymphoma and high-efficiency, low-toxicity pretreatment regimen, ABMT was performed on 11 malignant lymphomas with poor prognostic factors. Of the 11 patients, 10 were initially treated and 1 was relapsed. The median age at transplantation was 27 (19 to 37) years old. The pretreatment regimen was mainly for whole body irradiation (8 Gy) and high-dose chemotherapy (Mel140 mg/m 2 +Vp 16200 mg or +Ara-C1g/m 2 +CTX 60 mg/kg). After hematopoietic reconstitution, the tumor was locally supplemented with 25-30 Gy. All hematopoietic function was reconstructed in all patients after transplantation, and there was no transplant-related death. The median follow-up period was 35 (13-50) months. The complete remission rate was 81.8% and the recurrence rate was 18.2%. The ABMT of this pretreatment regimen has a good effect on highly malignant non-Hodgkin’s lymphoma and Hodgkin’s disease with poor response to conventional therapy.